Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Drilon
    Drilon
  2. Chaft
    Chaft
  3. Paik
    Paik
  4. D'Angelo
    D'Angelo
  5. Rudin
    Rudin
  6. Schoenfeld
    Schoenfeld
  7. Ladanyi
    Ladanyi
  8. O'Reilly
    O'Reilly
  9. Panageas
    Panageas
  10. Riely
    Riely

Groups

  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (44)
  3. Thoracic Oncology (44)
  4. GSK Faculty (4)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  6. Center for Molecular Imaging and Biotechnology (3)
  7. Early Drug Development Service (3)
  8. Hematologic Malignancies, Division of (3)
  9. Sarcoma Service (2)
  10. Tow Center for Developmental Oncology (TCDO) (2)
Search Within
  1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (44)
Groups
  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (44)
  3. Thoracic Oncology (44)
  4. GSK Faculty (4)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  6. Center for Molecular Imaging and Biotechnology (3)

More Groups

People
  1. Alexander Drilon (23)
  2. Matthew Hellmann (9)
  3. David Hyman (3)
  4. Jamie Chaft (3)
  5. Paul Paik (3)
  6. Adam Schoenfeld (2)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (13)
  4. 2021 (6)
  5. 2020 (12)
  6. 2019 (2)

More Years

Publishers
  1. S. Karger AG (44)

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; PeĢrol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
    Meeting Abstract

    Rieke, D. T.; Hong, D. S.; Drilon, A.; Tan, D. S.; Lin, J.; Kummar, S.; McDermott, R.; Berlin, J.; Italiano, A.; Lassen, U. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Rieke, D. T.; Lin, J. I.; Tan, D. S.; Kummar, S.; Patel, J. D.; Cermignani, L.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION cohorts A and C
    Meeting Abstract

    Griesinger, F.; Thomas, M.; Reinmuth, N.; Wermke, M.; Overbeck, T.; Alt, J.; Henschke, S.; Wehler, T.; Ochsenreither, S.; Garassino, M. C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Durability of efficacy with selpercatinib in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Drillon, A. E.; Subbiah, V.; Gautschi, O.; Tomasini, P.; De Braud, F. G.; Solomon, B.; Tan, D. S. W.; Alonso, G.; Wolf, J.; Park, K.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy(IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase 3 MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA
    Meeting Abstract

    Griesinger, F.; Tsuboi, M.; Weder, W.; Escriu, C.; Blakely, C.; He, J.; Dacic, S.; Yatabe, Y.; Zeng, L.; Walding, A.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) + platinum-etoposide (EP) in 1L extensivestage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; Broadhurst, H.; Lai, Z.; Whitston, D.; Paz-Ares, L.; Gay, C.; Byers, L.; Rudin, C. M.; Stewart, R.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 22965270 Unknown
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG